Ruthenium complexes are often investigated as potential replacements for platinum-based chemotherapeutics in hopes of identifying systems with improved tolerability in vivo and reduced susceptibility to cellular resistance mechanisms. Inspired by phenanthriplatin, a non-traditional platinum agent that contains only one labile ligand, monofunctional ruthenium polypyridyl agents have been developed, but until now, few demonstrated promising anticancer activity. Here we introduce a potent new scaffold, based on [Ru(tpy)(dip)Cl]Cl (tpy = 2,2':6',2''-terpyridine and dip = 4,7-diphenyl-1,10-phenanthroline) in pursuit of effective Ru(ii)-based monofunctional agents. Notably, the extension of the terpyridine at the 4' position with an aromatic ring...
Ruthenium(II) complexes are currently considered a viable alternative to the widely used platinum co...
International audienceNew ruthenium methyl-cyclopentadienyl compounds bearing bipyridine derivatives...
International audienceNew ruthenium methyl-cyclopentadienyl compounds bearing bipyridine derivatives...
International audienceDue to the increasing impact of cancer on worldwide mortality, more and more a...
Cancer is a worldwide public health crisis that requires new and improved drugs to be developed to e...
Cytostatic agents that interfere with specific cellular components to prevent cancer cell growth off...
Cytostatic agents that interfere with specific cellular components to prevent cancer cell growth off...
Cytostatic agents that interfere with specific cellular components to prevent cancer cell growth off...
The serendipitous discovery of cisplatin marks a milestone achievement in the field of medicinal ino...
International audienceTwo new ruthenium complexes, [Ru(h 5-Cp)(PPh 3)(2,2'-bipy-4,4'-R)] þ with R ¼-...
A great majority of the Ru complexes currently studied in anticancer research exert their antiprolif...
International audienceFour novel monocationic Ru(II) polypyridyl complexes were synthesized with the...
A great majority of the Ru complexes currently studied in anticancer research exert their antiprolif...
A great majority of the Ru complexes currently studied in anticancer research exert their antiprolif...
The clinical success of cisplatin, carboplatin, and oxaliplatin has sparked the interest of medicina...
Ruthenium(II) complexes are currently considered a viable alternative to the widely used platinum co...
International audienceNew ruthenium methyl-cyclopentadienyl compounds bearing bipyridine derivatives...
International audienceNew ruthenium methyl-cyclopentadienyl compounds bearing bipyridine derivatives...
International audienceDue to the increasing impact of cancer on worldwide mortality, more and more a...
Cancer is a worldwide public health crisis that requires new and improved drugs to be developed to e...
Cytostatic agents that interfere with specific cellular components to prevent cancer cell growth off...
Cytostatic agents that interfere with specific cellular components to prevent cancer cell growth off...
Cytostatic agents that interfere with specific cellular components to prevent cancer cell growth off...
The serendipitous discovery of cisplatin marks a milestone achievement in the field of medicinal ino...
International audienceTwo new ruthenium complexes, [Ru(h 5-Cp)(PPh 3)(2,2'-bipy-4,4'-R)] þ with R ¼-...
A great majority of the Ru complexes currently studied in anticancer research exert their antiprolif...
International audienceFour novel monocationic Ru(II) polypyridyl complexes were synthesized with the...
A great majority of the Ru complexes currently studied in anticancer research exert their antiprolif...
A great majority of the Ru complexes currently studied in anticancer research exert their antiprolif...
The clinical success of cisplatin, carboplatin, and oxaliplatin has sparked the interest of medicina...
Ruthenium(II) complexes are currently considered a viable alternative to the widely used platinum co...
International audienceNew ruthenium methyl-cyclopentadienyl compounds bearing bipyridine derivatives...
International audienceNew ruthenium methyl-cyclopentadienyl compounds bearing bipyridine derivatives...